The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Recent evidence points to Myc--a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers--as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy cells. Here we report on the action mechanism of...
Saved in:
| Main Authors: | Mauro Savino, Daniela Annibali, Nicoletta Carucci, Emilia Favuzzi, Michael D Cole, Gerard I Evan, Laura Soucek, Sergio Nasi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0022284&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tipping the MYC–MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC‐activated genes
by: Franz X Schaub, et al.
Published: (2014-11-01) -
Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
by: Giulio Donati, et al.
Published: (2023-05-01) -
The Interplay between Myc and CTP Synthase in Drosophila.
by: Gabriel N Aughey, et al.
Published: (2016-02-01) -
CX26 promotes pancreatic cancer progression by competitively inhibiting interaction of c-Myc with PSMD2 and enhancing c-Myc stability
by: Cheng He, et al.
Published: (2025-08-01) -
Beyond the Limit: MYC Mediates Tumor Immune Escape
by: Zhongyang Hong, et al.
Published: (2025-06-01)